Novel immunotherapy agent safe, shows promise against high-risk prostate cancers
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.
Materials provided by Johns Hopkins Medicine. Note: Content may be edited for style and length.
Source link aaaaa
